PDC Therapeutics

PDC Therapeutics is focused on pioneering advancements in biotechnology research, particularly in the development of targeted Polymer-Drug Conjugate (PDC) platform technologies. The company’s innovative approach aims to provide patients with therapies that offer an optimal therapeutic index, enhancing both efficacy and safety. PDC Therapeutics is committed to transforming the landscape of pharmaceutical treatments through its cutting-edge research and development efforts.

PDC Therapeutics' proprietary Sagitta® biodegradable conjugation platforms play a crucial role in the discovery and development of therapies. These platforms are designed to ensure no compromise on versatility in targeting capabilities, allowing for the creation of highly specific and effective treatments. Located in Lausanne, CH, PDC Therapeutics operates at the forefront of biotechnological innovation, driving progress in the field.

With a collaborative approach, PDC Therapeutics actively cooperates with multinational pharmaceutical companies through co-development programs. Supported by a board of scientific and supervisory experts with extensive industry experience from around the world, PDC Therapeutics is dedicated to pushing the boundaries of biotechnological solutions. We invite the manager of PDC Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further amplify your reach and impact.